News from debiopharm group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( Bloomberg:ALEMK@BB,RICS:ALEMK,ISIN:BE0003843605)

Jan 13, 2015, 10:00 ET

Debiopharm Diagnostics Leads Investment Round in GenePOC With Emerillon Capital

Debiopharm Diagnostics, part of Debiopharm Group™, is proud to be the lead investor in GenePOC, which is developing a highly...

Jan 13, 2015, 10:00 ET

Debiopharm Diagnostics mène un tour d'investissement dans la société GenePOC avec Emerillon Capital

GenePOC est une société canadienne qui a développé une plateforme de diagnostics moléculaires (MDx) rapide, innovante et...

Jan 12, 2015, 02:30 ET

Debiopharm Group™ Regains Full Rights to Alisporivir Program

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that it has updated its arrangement...

Jan 12, 2015, 02:30 ET

Debiopharm Group™ récupère les droits complets du programme sur l'Alisporivir

- Novartis restitue l'Alisporivir (DEB025) à Debiopharm Group™ , y compris tous les droits pour le virus de l'hépatite C et...

Jan 08, 2015, 03:00 ET

FDA Grants Fast Track Designation to Debiopharm Group's Antibiotic Debio 1450

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that the US...

Jan 08, 2015, 03:00 ET

La FDA accorde la désignation Fast Track à l'antibiotique Debio 1450 de Debiopharm Group

- Le Debio 1450, un inhibiteur de FabI administré par voie orale/IV actif contre toutes les espèces de staphylocoques, a reçu la...

Nov 18, 2014, 07:00 ET

Debiopharm Group™ Presents Advances of two key Oncology Clinical Programs at the 26th EORTC-NCI-AACR Symposium in Barcelona

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs along with companion...

Oct 07, 2014, 08:00 ET

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical...

Sep 30, 2014, 08:00 ET

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada

Trelstar® (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer,[1] is now...

Sep 26, 2014, 03:00 ET

Presented by the Japanese Cancer Association and Debiopharm Group™, the 'JCA-Mauvernay Award 2014' goes to Doctors Hara and Shibata

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical...

Sep 17, 2014, 03:00 ET

Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument

Debiopharm Diagnostics, part of Debiopharm Group™, is proud to congratulate Biocartis commitment in shipping its first...

Sep 04, 2014, 07:00 ET

Debiopharm Group™'s Innovative Antibiotic Debio 1450 - Developed From its Proprietary Platform Fabiotics - Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical...

Jun 26, 2014, 11:00 ET

Debiopharm Group and Nobelex Biotech Start Two Collaborations on Development of New Antibiotics Against N. Gonorrhoeae and Enteric Species

Debiopharm Group™ (Debiopharm), a Switzerland-based global biopharmaceutical company developing prescription drugs that target unmet...

Jun 24, 2014, 11:00 ET

Debiopharm Group and TCG Lifesciences Ltd. Announce Successful Completion of First Phase of Research Collaboration on Discovery of Novel Antibiotics

Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription...

May 28, 2014, 08:00 ET

Debiopharm Group™ Moves Forward Three of Its Oncology Clinical Programs and Will Present the Recent Progresses at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs...

May 27, 2014, 02:00 ET

Orient EuroPharma and Debiopharm Group™ Announce Their Partnership and the Launch of Pamorelin® LA in Singapore

Orient EuroPharma Co., Ltd. (Orient EuroPharma) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries...

May 06, 2014, 03:00 ET

Debiopharm Group™ and Yale University extend and broaden their collaboration for the discovery and development of MIF inhibitors to treat autoimmune and inflammatory diseases

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs...

Apr 08, 2014, 03:30 ET

Curis and Debiopharm Group Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014

Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and...

Apr 02, 2014, 01:30 ET

Evotec and Debiopharm Group™ to Collaborate on Development of New Treatment for Cancer

   - Innovative partnership based on Evotec's Target X projects  - Evotec and Debiopharm to share discovery and...

Mar 06, 2014, 03:00 ET

Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies active in drug development, GMP manufacturing of...